The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yue, Fu, Yucheng, Zeng, Yue, Liu, Xiaohan, Peng, Yurong, Hu, Chunhong, Deng, Chao, Qiu, Zhenhua, Zou, Jian, Liu, Yuxuan, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900392/
https://www.ncbi.nlm.nih.gov/pubmed/35255999
http://dx.doi.org/10.1186/s40364-022-00355-7
_version_ 1784664103203110912
author Pan, Yue
Fu, Yucheng
Zeng, Yue
Liu, Xiaohan
Peng, Yurong
Hu, Chunhong
Deng, Chao
Qiu, Zhenhua
Zou, Jian
Liu, Yuxuan
Wu, Fang
author_facet Pan, Yue
Fu, Yucheng
Zeng, Yue
Liu, Xiaohan
Peng, Yurong
Hu, Chunhong
Deng, Chao
Qiu, Zhenhua
Zou, Jian
Liu, Yuxuan
Wu, Fang
author_sort Pan, Yue
collection PubMed
description Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the “seed-soil-environment”, generalizes primary resistance to immunotherapy, and summarizes the integration of markers.
format Online
Article
Text
id pubmed-8900392
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89003922022-03-17 The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer Pan, Yue Fu, Yucheng Zeng, Yue Liu, Xiaohan Peng, Yurong Hu, Chunhong Deng, Chao Qiu, Zhenhua Zou, Jian Liu, Yuxuan Wu, Fang Biomark Res Review Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the “seed-soil-environment”, generalizes primary resistance to immunotherapy, and summarizes the integration of markers. BioMed Central 2022-03-07 /pmc/articles/PMC8900392/ /pubmed/35255999 http://dx.doi.org/10.1186/s40364-022-00355-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Pan, Yue
Fu, Yucheng
Zeng, Yue
Liu, Xiaohan
Peng, Yurong
Hu, Chunhong
Deng, Chao
Qiu, Zhenhua
Zou, Jian
Liu, Yuxuan
Wu, Fang
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
title The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
title_full The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
title_fullStr The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
title_full_unstemmed The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
title_short The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
title_sort key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900392/
https://www.ncbi.nlm.nih.gov/pubmed/35255999
http://dx.doi.org/10.1186/s40364-022-00355-7
work_keys_str_mv AT panyue thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT fuyucheng thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT zengyue thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT liuxiaohan thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT pengyurong thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT huchunhong thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT dengchao thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT qiuzhenhua thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT zoujian thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT liuyuxuan thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT wufang thekeytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT panyue keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT fuyucheng keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT zengyue keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT liuxiaohan keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT pengyurong keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT huchunhong keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT dengchao keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT qiuzhenhua keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT zoujian keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT liuyuxuan keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer
AT wufang keytoimmunotherapyhowtochoosebettertherapeuticbiomarkersforpatientswithnonsmallcelllungcancer

Ejemplares similares